Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.66 |
| ▸ | MAPT | P10636 | 8/20 | 0.63 |
| ▸ | MEN1 | O00255 | 5/20 | 0.63 |
| ▸ | LMNA | P02545 | 4/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | CASP7 | P55210 | 1/20 | 0.62 |
| ▸ | CASP6 | P55212 | 1/20 | 0.62 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.62 |
| ▸ | ACP1 | P24666 | 1/20 | 0.60 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | CSNK1D | P48730 | 4/20 | 0.59 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15489028 | 0.92 | KMT2A (0.63) | KMT2AMAPTMEN1LMNAALDH1A1 | |
| SCHEMBL20862967 | 0.92 | KMT2A (0.63) | KMT2AMAPTMEN1LMNAALDH1A1 | |
| SCHEMBL15063121 | 0.90 | MAPT (0.74) | KMT2AMAPTMEN1LMNAALDH1A1 | |
| SCHEMBL15063122 | 0.89 | MAPT (0.66) | KMT2AMAPTMEN1LMNAALDH1A1 | |
| SCHEMBL15083819 | 0.88 | MAPT (0.65) | KMT2AMAPTMEN1LMNAALDH1A1 | |
| SCHEMBL18700065 | 0.87 | MAPT (0.64) | KMT2AMAPTMEN1LMNAALDH1A1 | |
| SCHEMBL15113372 | 0.85 | CSNK1D (0.81) | MAPTGAACSNK1D | |
| SCHEMBL15112849 | 0.85 | CSNK1D (0.70) | KMT2AMAPTMEN1LMNAALDH1A1 | |
| SCHEMBL15113374 | 0.84 | GAA (0.64) | KMT2AMAPTMEN1LMNAGAA | |
| SCHEMBL15112843 | 0.84 | CSNK1D (0.71) | MAPTLMNAGAACSNK1DPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170152485-A1 | Method for Inducing Cardiac Differentiation of Pluripotent Stem Cell with Low-Molecular Compounds | KYOTO UNIVERSITY (JP) | 2017-06-01 | — | — | US | disclosed |
| US-20170152485-A1 | Method for Inducing Cardiac Differentiation of Pluripotent Stem Cell with Low-Molecular Compounds | KYOTO UNIVERSITY (JP) | 2017-06-01 | — | — | US | disclosed |
| US-9587220-B2 | Method for inducing cardiac differentiation of pluripotent stem cell | KYOTO UNIVERSITY (JP) | 2017-03-07 | — | — | US | disclosed |
| US-9587220-B2 | Method for inducing cardiac differentiation of pluripotent stem cell | KYOTO UNIVERSITY (JP) | 2017-03-07 | — | — | US | disclosed |
| US-9499790-B2 | Method for promoting differentiation of pluripotent stem cells into cardiac muscle cells | KYOTO UNIVERSITY (JP) | 2016-11-22 | — | — | US | disclosed |
| US-20160002600-A1 | COMPOSITION FOR PROMOTING CARDIAC DIFFERENTIATION OF PLURIPOTENT STEM CELL COMPRISING EGFR INHIBITOR | KYOTO UNIVERSITY (JP) | 2016-01-07 | — | — | US | disclosed |
| US-20160002600-A1 | COMPOSITION FOR PROMOTING CARDIAC DIFFERENTIATION OF PLURIPOTENT STEM CELL COMPRISING EGFR INHIBITOR | KYOTO UNIVERSITY (JP) | 2016-01-07 | — | — | US | disclosed |
| US-8658425-B2 | Method for promoting differentiation of pluripotent stem cells into cardiac muscle cells | KYOTO UNIVERSITY (JP) | 2014-02-25 | — | — | US | disclosed |
| US-8658425-B2 | Method for promoting differentiation of pluripotent stem cells into cardiac muscle cells | KYOTO UNIVERSITY (JP) | 2014-02-25 | — | — | US | disclosed |
| US-20130183753-A1 | METHOD FOR PROMOTING DIFFERENTIATION OF PLURIPOTENT STEM CELLS INTO CARDIAC MUSCLE CELLS | KYOTO UNIVERSITY (JP) | 2013-07-18 | — | — | US | disclosed |
| US-20130183753-A1 | METHOD FOR PROMOTING DIFFERENTIATION OF PLURIPOTENT STEM CELLS INTO CARDIAC MUSCLE CELLS | KYOTO UNIVERSITY (JP) | 2013-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130183753-A1 | METHOD FOR PROMOTING DIFFERENTIATION OF PLURIPOTENT STEM CELLS INTO CARDIAC MUSCLE CELLS | TNNI3, MYLK2, TNNT2 | KMT2A 3036/4885MAPT 4471/4885MEN1 4824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.